Cannabis Trademarks Not Stoned by PTO
Client Alert | 1 min read | 05.07.19
In new guidelines issued this past Thursday, May 2, 2019, the United States Patent & Trademark Office clarified the procedure for examining trademarks for cannabis-derived goods, services involving cannabis, and cannabis production. These guidelines explain that the 2018 Farm Bill exempts hemp (defined as cannabis plants and derivatives such as CBD that contain no more than 0.3 percent THC on a dry-weight basis) from the definition of marijuana in the Controlled Substances Act (21 U.S.C. § 801 et seq.)(CSA).
Thus, for applications that identify goods and/or related services encompassing cannabis or CBD, the 2018 Farm Bill potentially removes the CSA as a ground for refusal of registration under the following conditions:
- The goods and/or related services are derived from hemp.
- The identification of goods and/or services specify that the hemp products contain less than 0.3 percent THC.
- The application was filed on or after December 20, 2018, except that for applications filed before December 20, 2018, applicants have the option of amending the filing date and filing basis of the application to overcome the CSA as a ground of refusal.
Despite these guidelines, applicants should be aware that hemp related goods and/or services may still raise lawful-use issues under other laws, including the Federal Food Drug and Cosmetic Act (FDCA).
A link to the guidelines may be accessed here: USPTO Examination Guide 1-19.
Contacts
Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 1 min read | 04.17.26
Client Alert | 3 min read | 04.17.26
Client Alert | 2 min read | 04.16.26


